Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Lynx1 Capital Management LP 13F Holdings -- Portfolio & Top Positions (2026-06-30)

Lynx1 Capital Management LP (CIK 1910456) reported $865.5M across 27 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: GHRS ($356.5M, 41.19%), CGEM ($163.2M, 18.86%), STOK ($132.1M, 15.27%), AGIO ($126.5M, 14.62%), CCCC ($34.2M, 3.95%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1GHRSGH RESEARCH PLC$356.5M41.19%13.3MAdded
2CGEMCULLINAN THERAPEUTICS INC$163.2M18.86%9.0MHold
3STOKSTOKE THERAPEUTICS INC$132.1M15.27%4.0MTrimmed
4AGIOAGIOS PHARMACEUTICALS INC$126.5M14.62%3.4MAdded
5CCCCC4 THERAPEUTICS INC$34.2M3.95%7.3MAdded
6KRROKORRO BIO INC$20.3M2.34%1.5MHold
7TCRXTSCAN THERAPEUTICS INC$7.9M0.91%8.0MHold
8DTILPRECISION BIOSCIENCES INC$7.5M0.86%950,466Trimmed
9NEUPNEUPHORIA THERAPEUTICS INC$3.8M0.44%875,328Hold
10PASGPASSAGE BIO INC$3.3M0.38%673,759Added
11CGONCG ONCOLOGY INC$2.2M0.26%31,391Trimmed
12PLRXPLIANT THERAPEUTICS INC$2.0M0.24%1.8MNew
13TRDAENTRADA THERAPEUTICS INC$1.3M0.15%178,606Trimmed
14VYNEVYNE THERAPEUTICS INC$1.1M0.12%1.6MHold
15PRQRPROQR THRAPEUTICS N V$969,8280.11%521,413Added
16TRAWTRAWS PHARMA INC$471,8010.05%559,470Added
17ABSIABSCI CORPORATION$246,2300.03%21,245Hold
18FHTXFOGHORN THERAPEUTICS INC$300,5490.03%61,588New
19HOWLWEREWOLF THERAPEUTICS INC$236,7370.03%657,786Hold
20XNCRXENCOR INC$292,9230.03%18,194Trimmed
21IMTXIMMATICS N.V$235,3810.03%23,236Trimmed
22DNLIDENALI THERAPEUTICS INC$299,8440.03%11,658Trimmed
23AVTXAVALO THERAPEUTICS INC$186,6480.02%10,100New
24NUVBNUVATION BIO INC$91,0450.01%16,029New
25EPRXEUPRAXIA PHARMACEUTICALS INC$66,1000.01%10,000New

Source: SEC Form 13F filings · as of 2026-06-30